TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive Charles Moertel, Mayo Clinic Investigator, Advocate Of Rigorous Trials, Dead At 66 July 8, 1994
TCL Archive FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review. March 23, 2001
TCL Archive FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say January 26, 1996
